The global alpha 1 antitrypsin deficiency (AATD) treatment market is witnessing considerable growth, supported by the rising prevalence of respiratory disorders, growing awareness of AAT deficiency, and advancements in treatment options. According to a Transparency Market Research report, the market was valued at approximately US$1.4 billion in 2018 and was projected to expand at a 10.1% CAGR between 2019 and 2027.
Alpha 1 antitrypsin deficiency is a genetic disorder that can increase the risk of lung and liver diseases. Increasing incidence of respiratory conditions, particularly chronic obstructive pulmonary disease (COPD), has contributed to greater attention toward AATD diagnosis and treatment. The World Health Organization has highlighted COPD as a major global health concern, affecting millions of people worldwide.
Key Factors Driving Market Growth
One of the major factors supporting the AATD treatment market is the growing awareness surrounding the disease and available therapeutic options. Improved diagnostic capabilities are also helping identify patients who may previously have remained undiagnosed.
Government initiatives aimed at strengthening plasma collection and expanding the availability of blood-derived products are another important market driver. Since several AATD therapies rely on plasma-derived alpha-1 proteinase inhibitors, improvements in plasma-product infrastructure can support treatment availability.
The increasing use of combination therapies for respiratory disorders is also expected to create opportunities for market participants. Treatment approaches may include therapies designed to manage respiratory symptoms as well as augmentation therapy for eligible patients with severe AAT deficiency.
However, the market also faces challenges. Treatment-related adverse effects, including chest pain, sinusitis, back pain, and rhinorrhea, may affect patient acceptance and treatment continuity. In addition, the high cost of certain therapies and relatively low diagnosis rates remain significant barriers to wider market penetration.
Get Sample PDF Copy: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13214
Treatment and Distribution Segmentation
The alpha 1 antitrypsin deficiency treatment market can be segmented according to treatment type, route of administration, and end user.
By treatment type, major categories include bronchodilators, oxygen therapy, corticosteroids, and augmentation therapy. Augmentation therapy includes products such as Prolastin, Glassia, Aralast, and Zemaira or Respreeza.
Based on the route of administration, the market is divided into inhalation, parenteral, and oral therapies. Hospitals, specialty clinics, and pharmacies represent key end-user segments, reflecting the different settings in which diagnosis, treatment, and ongoing patient management take place.
Regional Market Outlook
North America has historically represented a leading regional market for AATD treatments. Factors contributing to the region's market position include investments in research and development, improved diagnostic capabilities, and the prevalence of respiratory diseases.
Europe is also expected to offer substantial growth opportunities. Increasing awareness of AAT deficiency, research initiatives focused on respiratory diseases, and an aging population are among the factors supporting demand for diagnosis and treatment.
Other regions, including Asia Pacific, Latin America, and the Middle East and Africa, are also gaining attention as healthcare infrastructure and awareness of rare and genetic diseases improve.
Competitive Landscape
The global alpha 1 antitrypsin deficiency treatment market features several established pharmaceutical and biotechnology companies. Key participants identified in the market include Takeda Pharmaceutical Company Limited, Kamada Pharmaceuticals, AstraZeneca, Pfizer, LFB Biomedicaments, Grifols, CSL Behring, GlaxoSmithKline, Boehringer Ingelheim, and Teva Pharmaceutical Industries, among others.
Companies are focusing on regulatory approvals, product development, strategic collaborations, mergers, and acquisitions to strengthen their market presence. For example, Kamada extended its strategic supply agreement with Takeda in 2019 for the production of Glassia, while CSL Behring received U.S. regulatory approval in 2019 for additional vial sizes of Zemaira.
Overall, rising disease awareness, improvements in diagnosis, expanding plasma-derived product infrastructure, and ongoing pharmaceutical research are expected to remain important factors shaping the future of the alpha 1 antitrypsin deficiency treatment market.
Media Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453